The validation of anxiety rating scales in Parkinson's disease

Completed

• Conditions: anxiety; parkinson's disease; 10028037; 10002861

• Registration Number: NL-OMON32820
• Lead Sponsor: Academisch Ziekenhuis Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

- Idiopathic Parkinson's Disease according to the Queens Square Brain Bank criteria
- Informed consent

Exclusion Criteria

- patients with neurodegenerative disorders other than PD
- patients under 50 years of age
- dementia or severe cognitive decline, operationalised as an Mini Mental State Exam score < 23

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary study parameters are the validity and reliability of the anxiety<br /><br>rating scales used resp; the Neuropsychiatric Invertory, anxiety section, the<br /><br>Hamilton Anxiety Rating Scale. the Clinical Global Impression Scale, the Beck<br /><br>Anxiety Inventory and the Hospital Anxiety and Depression Scale.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secundary study parameters are:<br /><br>- prevalence rates of van anxiety disorders<br /><br>- atypical anxiety syndromes will be looked into by exploratory clusteranalysis<br /><br>of items on the various anxiety scales<br /><br>- anxiety states limited to 'off'periods and/or dyskinesia will be described by<br /><br>looking at score patterns across the additional questions pertaining to<br /><br>response fluctuations (see appendix protocol)</p><br>